In December 2018, the FDA announced its guidance for industry on the interpretation of the “Deemed to be a License” provision in section 7002(e) of the Biologics Price Competition and Innovation Act. The bill introduced this week would codify those guidelines, as they pertain to insulin, into law to prevent any future administrations from revoking them.
The bipartisan co-chairs of the Congressional Diabetes Caucus introduced a bill this week to make permanent new FDA guidance on the transition of insulin to regulation as a biologic. The bill is aimed at preventing a future executive branch of government from trying to revoke the policy.
Representatives Diana DeGette, D-Colorado, and Tom Reed, R-New York, introduced the legislation.
“We know that one of the best ways to reduce the cost of insulin is to increase competition,” DeGette said in a statement. “Despite insulin being available for nearly 100 years now, there are still only [3] companies that manufacture the drug here in the U.S. and only [1] generic version of the drug available to consumers.”
In December 2018, the FDA announced its guidance for industry on the interpretation of the “Deemed to be a License” provision in section 7002(e) of the Biologics Price Competition and Innovation Act (BPCIA). The bill introduced this week would codify those guidelines, as they pertain to insulin, into law to prevent any future administrations from revoking them.
The FDA guidance discusses how the agency plans to transfer drugs previously approved under new drug applications (NDAs) to biologic license applications (BLAs) in March 2020 as part of the Biologics Price Competition and Innovation Act. The guidance makes clear that NDAs transitioning to BLAs will not gain an additional 12 years of patent exclusivity because of the switch.
The need to codify the guidance comes as industry groups, such as Pharmaceutical Research and Manufacturers of America and the Biotechnology Innovation Association, as well as other biopharma companies, are raising questions and concerns about how the FDA has interpreted the law in terms of reference product exclusivity.
On Tuesday, DeGette chaired a meeting of the Oversight and Investigations subcommittee, part of the Committee on Energy and Commerce, and heard testimony about how the high price of insulin is forcing patients with diabetes to skip doses or go without.
In other insulin cost news this week, Cigna and its pharmacy benefit manager Express Scripts said they are launching a program for patients enrolled in commercial plans so that they pay no more than $25 for a 30-day supply of insulin.
In a statement, the companies said the average out-of-pocket cost for insulin was $41.50 for a 30-day supply last year; under the new program, eligible patients will save approximately 40%. “In most cases, people who use insulin will see lower out-of-pocket costs without any increased cost to the plan,” the companies said.
A company spokeswoman told The American Journal of Managed Care®, a sister publication of The Center for Biosimilars®, that a complete list of products is not yet available, but that the companies are planning to have “all forms of insulin” (short acting, basal, and intermediate) available at the lower price.
The program is not available to people enrolled in government health plans.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.